Ricci Giovanna, Gibelli Filippo, Sirignano Ascanio
Section of Legal Medicine, School of Law, University of Camerino, IT-62032 Macerata, Italy.
Bioengineering (Basel). 2023 Sep 7;10(9):1052. doi: 10.3390/bioengineering10091052.
Three-dimensional bioprinting is a rapidly evolving technology that holds the promise of addressing the increasing demand for organs, tissues, and personalized medicine. By employing computer-aided design and manufacturing processes, 3D bioprinting allows for the precise deposition of living cells, biomaterials, and biochemicals to create functional human tissues and organs. The potential applications of this technology are vast, including drug testing and development, disease modeling, regenerative medicine, and ultimately, organ transplantation. However, as with any groundbreaking technology, 3D bioprinting presents several ethical, legal, and regulatory concerns that warrant careful consideration. As the technology progresses towards clinical applications, it is essential to address these challenges and establish appropriate frameworks to guide the responsible development of 3D bioprinting. This article, utilizing the Arksey and O'Malley scoping review model, is designed to scrutinize the bioethical implications, legal and regulatory challenges, and medico-legal issues that are intertwined with this rapidly evolving technology.
三维生物打印是一项快速发展的技术，有望满足对器官、组织和个性化医疗日益增长的需求。通过采用计算机辅助设计和制造工艺，三维生物打印能够精确沉积活细胞、生物材料和生化物质，以创建功能性人体组织和器官。这项技术的潜在应用非常广泛，包括药物测试与开发、疾病建模、再生医学，最终还可用于器官移植。然而，与任何开创性技术一样，三维生物打印也带来了一些伦理、法律和监管方面的问题，值得仔细考量。随着该技术向临床应用迈进，应对这些挑战并建立适当的框架以指导三维生物打印的负责任发展至关重要。本文利用阿克西和奥马利的范围审查模型，旨在审视与这项快速发展的技术交织在一起的生物伦理影响、法律和监管挑战以及法医学问题。
